Curenex Skin Booster | Ingredients, Effect and Usage

Quick Answer

What are the key ingredients in Curenex skin booster? Curenex is a salmon-derived polynucleotide (PN) skin booster manufactured by KD Bio Inc. (South Korea) that contains three active components: polydeoxyribonucleotide (PDRN) derived from salmon DNA, hyaluronic acid (HA), and a proprietary peptide complex. The PDRN component — extracted from Oncorhynchus keta (chum salmon) sperm cells through a patented purification process — activates A2A purinergic receptors in human fibroblasts, stimulating collagen type I and III synthesis and promoting wound healing at the cellular level. The HA component provides immediate hydration by binding up to 1,000 times its weight in water within the dermal matrix. Curenex is available in two formulations: Curenex (2ml vial for mesotherapy) and Curenex Skin Booster (pre-filled syringe). Standard treatment protocols recommend 3–4 sessions at 2-week intervals.

Curenex is a Korean complex skin booster that integrates repair and brightening. Its core ingredients include PDRN (Salmon DNA), 15 types of peptides, Glutathione, and Hyaluronic Acid. In clinical use, it is recommended to be administered by a professional physician through mesotherapy. A standard course usually consists of 3-5 sessions, with an interval of 2-3 weeks between each session.

Ingredients

Each 5ml of Curenex solution contains 0.2% concentration of PDRN (Polydeoxyribonucleotide), extracted from salmon sperm DNA. The formula blends 15 types of biomimetic peptides (such as Oligopeptide-1, Polypeptide-11), as well as Glutathione, non-cross-linked Hyaluronic Acid, and collagen.

PDRN

PDRN is a biopolymer fragment derived from salmon sperm DNA, with a molecular weight distribution between 50 to 1500 kDa. Its specific nucleotide sequence has a homology of over 95% with human DNA base sequences. Once injected into the dermis, the substance does not produce immune rejection and can physically bind with adenosine A2A receptors on the cell surface. Binding with A2A receptors promotes the release of Vascular Endothelial Growth Factor (VEGF). VEGF induces microvascular regeneration in aging dermal tissue, improving local blood circulation. Histological data shows that the microvascular density in PDRN-treated areas is approximately 30% higher than in untreated areas. Each 5ml of Curenex solution contains a specific ratio of PDRN. When substrate fragments enter the interstitial space, they provide ready-made nucleotide substrates through the “Salvage Pathway”. Cells do not need to consume large amounts of energy to synthesize DNA from scratch; utilizing these fragments for repair shortens the cell cycle interphase. Experiments observed that this physiological activity saves approximately 50% of the metabolic energy of fibroblasts. The remaining energy is redirected toward synthesizing the extracellular matrix. Within 48 to 72 hours post-treatment, the proliferation rate of dermal fibroblasts increases by approximately 20%.

Molecular weight range: 50-1500 kDa.
DNA homology: Higher than 95%.
Thermal stability: Maintains structural stability in a 75°C environment.
Physiological receptor: Adenosine A2A receptor.
pH range: Neutral range of 6.5 to 7.5.

Proliferated fibroblasts begin secreting Type I collagen and elastin. Clinical biopsies show that after 3 PDRN treatments, dermal thickness increases by an average of 15% to 20%. The arrangement of collagen fibers transforms from a chaotic state to a neat mesh structure, enhancing the physical tensile strength of the skin. It downregulates the expression of pro-inflammatory cytokines (such as TNF-α and IL-6) while upregulating levels of the anti-inflammatory factor IL-10. Saline-controlled experiments confirmed that the PDRN treatment group accelerated wound healing speed by about 40%. The mechanism lies in accelerating the migration process of epithelial cells. Due to its stable nucleotide structure, the half-life of this ingredient in subcutaneous tissue is sufficient to maintain long-term biostimulation effects.

VEGF upregulation rate: Induced angiogenesis speed increases by 35%.
Fibroblast proliferation: Cell count increases by 30% within 7 days.
Melanin inhibition: Works with Glutathione to reduce tyrosinase activity.
Water loss rate: After strengthening the barrier, Transepidermal Water Loss (TEWL) decreases by 12%.
Collagen density: Density increases by 22% after one month of continuous use.

Elastin induced by PDRN increases the resilience of the dermis. Measuring instruments show a significant jump in skin elasticity coefficients after the treatment course. This ingredient also participates in the metabolic regulation of melanocytes. By improving the dermal microenvironment, it reduces pigmentation caused by chronic inflammation. In clinical observations, accompanied by the subsiding of inflammation, the Erythema Index (E-index) on the skin surface decreased by an average of 15%. Curenex combines PDRN with 15 types of peptides to create a synergistic effect. Peptides act as signaling molecules, coordinating with the nucleotide substrates provided by PDRN. One side sends synthesis instructions, while the other provides the raw materials, completing the full chain from signal transduction to substance construction. Due to the anti-inflammatory properties of PDRN, redness and swelling post-injection usually subside within 24 hours. This characteristic makes it suitable for tissue reconstruction in sensitive skin types.

Injection depth: Mid-to-deep dermis (approximately 1.0-1.5mm).
Single dose: 5ml/, distributed across the face.
Onset time: Cell metabolism begins to accelerate within 48 hours.
Course recommendation: Clinical introduction every 3-4 weeks.

PDRN provides protective effects against DNA damage caused by UV rays. It reduces the formation of thymine dimers by enhancing the Nucleotide Excision Repair (NER) mechanism. Long-term monitoring found that skin treated with this ingredient shows significantly enhanced tolerance to photoaging. In dry environments, PDRN coordinates with non-cross-linked hyaluronic acid to improve the osmotic pressure of the interstitial matrix. Moisture is locked within the collagen fiber mesh. This combination of physical filling and biological repair addresses the issue of long-term maintenance that simple hydration cannot achieve. Matrix Metalloproteinases (MMPs) activity in the dermis is effectively inhibited. MMPs are the main enzymes responsible for breaking down collagen. PDRN slows the rate of collagen loss by regulating the ratio between MMPs and Tissue Inhibitors of Metalloproteinases (TIMPs).

Glutathione

Glutathione is composed of glutamic acid, cysteine, and glycine, with a precise molecular weight of 307.32 g/mol. Within the Curenex formulation, it exists in the reduced form (GSH), containing highly active thiol (-SH) functional groups. After entering the dermis, GSH is distributed within the cell matrix within 15 to 30 minutes. The active center of tyrosinase contains dual copper ions (Cu2+); GSH undergoes a chelation reaction with copper ions through steric hindrance effects. Experimental measurements show that a 0.1mM concentration of GSH can decrease the catalytic rate of tyrosinase by approximately 85%. The decrease in catalytic rate alters the melanin synthesis pathway. Dopaquinone within melanosomes would normally polymerize into dark brown eumelanin. The intervention of GSH forces dopaquinone to bind with cysteine, generating cysteinyl-dopa, which subsequently converts into red-yellow pheomelanin.

In vitro cell cultures show that after 72 hours, the synthesis ratio of eumelanin to pheomelanin in melanocytes treated with GSH reversed from 3:1 to 1:2.5.

This change in synthesis ratio is optically expressed as an increase in skin lightness (L* value). Spectrophotometer measurements indicate that after continuous introduction of GSH, local skin light reflectance increased by about 12%. The density of pigment particles in the basal layer of the epidermis decreases accordingly, with melanin deposits per square millimeter reduced by about 20%. In addition to intervening in pigment synthesis, glutathione performs the task of clearing Reactive Oxygen Species (ROS) within the cell. UVA radiation (320-400nm) stimulates cells to produce hydrogen peroxide and hydroxyl radicals. GSH acts as an electron donor, transferring a single electron to free radicals to reduce them into harmless water molecules. After completing the electron transfer, two molecules of reduced GSH oxidize and bind to form one molecule of disulfide (GSSG). Intracellular glutathione reductase, with the participation of Nicotinamide Adenine Dinucleotide Phosphate (NADPH), re-reduces GSSG to GSH at a rate of 100 molecules per second.

Molecular weight parameter: 307.32 g/mol.
Active ingredient form: L-Glutathione reduced form.
Isoelectric point (pI): 5.93.
Half-life: Approximately 45 to 60 minutes in the subcutaneous tissue environment.
Redox potential: -240 mV.

Tissue section analysis proves that in the presence of GSH, the rate of UV-induced collagen cross-linking breakage decreased by 35%. Malondialdehyde (MDA), a marker for lipid peroxidation in cell membranes, decreased by approximately 40%. The hydrophilicity of large peptide molecules makes it difficult for them to penetrate the intact stratum corneum barrier. Curenex bypasses the physical limitation of epidermal absorption—which is only 1-2%—through microneedle skin penetration. The GSH-containing solution is delivered into the light reticular structure of the dermis at a depth of 1.2mm with a single-point dose of 0.02ml.

In the microvascular network at a depth of 1.2mm, the diffusion coefficient of GSH reaches its maximum value, with a targeted coverage rate of over 90% of the injection area within 48 hours.

The reticular structure contains a large number of macrophages. GSH upregulates the phagocytic activity of macrophages, accelerating the clearance of already formed melanin debris. Clinical tracking using VISIA skin analysis recorded an average 18% decrease in pigment spot contrast within four weeks. Large peptides create complementarity in biochemical pathways with the peptides and hyaluronic acid in the formula. The hydration environment provided by hyaluronic acid provides the osmotic pressure conditions for the diffusion of GSH. The survival rate of new cells stimulated by peptides increases by 25% in the low oxidative stress environment provided by GSH.

L* value increase: Average brightness index of the treated area increased by 12%.
MDA concentration: Lipid peroxide marker decreased by 40%.
Enzyme activity downregulation: Tyrosinase catalytic efficiency decreased by 85%.
Target depth: 1.2mm superficial dermis.

The liver is the main organ for human GSH synthesis, but as age increases, daily endogenous synthesis decreases at a rate of 1% per year. Local dermal GSH concentrations fall below the 2.5mM threshold required to maintain a bright complexion after age 35. The metabolites of exogenous GSH are free amino acids, which can be completely decomposed through the tricarboxylic acid cycle, leaving no tissue residual toxicity. In a single 5ml treatment session, the formulated GSH concentration is strictly controlled within the 280-300 mOsm/kg range to avoid disrupting cell osmotic balance. After a 14-day metabolic cycle, melanocytes altered by GSH will shed along with epidermal turnover. The renewal rate of keratinocytes stabilizes at around 28 days with the assistance of GSH.

Keratinocyte arrangement under the microscope shows more regular cell edges after GSH intervention, with the light scattering rate through the stratum corneum decreasing by about 15%.

Long-term exposure to environmental pollutants like car exhaust leads to PM2.5 particle attachment on the skin surface. The thiol group of GSH can capture heavy metal ions (such as lead and mercury), forming water-soluble mercaptide complexes. Mercaptide complexes are subsequently discharged from local tissue through the lymphatic microcirculation system within 72 hours. Under a storage environment of 25°C, GSH in sealed can maintain biological stability for up to 24 months.

15 Types of Peptides

A single 5ml of Curenex integrates 15 types of highly active biomimetic peptides, with molecular weights generally controlled below 500 Daltons. This microscopic molecular structure allows them to bypass complex cellular barriers and penetrate the dermis at a depth of 1.2mm within 10 minutes after microneedle or water-light introduction. Among the 15 ingredients, Oligopeptide-1 (EGF) is a single-chain peptide composed of 53 amino acids, primarily tasked with docking with Epidermal Growth Factor Receptors (EGFR). Clinical experimental records show that a concentration of 0.1ng/ml of Oligopeptide-1 can increase basal cell division speed by about 25%. As the cell renewal cycle is shortened from the standard 28 days to about 21 days, old and damaged stratum corneum is replaced faster, and fine skin textures are physically smoothed within 14 days. Following this, Palmitoyl Pentapeptide-4 (commonly known as Matrixyl) increases its lipophilicity by linking with a palmitic acid chain. At an extremely low concentration of 3ppm, this substance can induce fibroblasts to synthesize Type I collagen, Type IV collagen, and Glycosaminoglycans (GAGs). Laboratory data shows that after 4 months of continuous action, the overall thickness of the dermis increases by an average of 6.5%, directly enhancing the skin’s physical resistance to external pressure and gravity.

Acetyl Hexapeptide-8: Mimics the SNAP-25 protein terminal, reducing facial muscle contraction intensity by about 30%, thereby smoothing dynamic wrinkles.
Copper Tripeptide-1 (GHK-Cu): Chelates divalent copper ions, increasing lysyl oxidase activity and accelerating the mesh cross-linking of collagen fibers.
Palmitoyl Tripeptide-1: Mimics collagen degradation fragments, feedback-tricking the skin into producing more new proteins.
Nonapeptide-1: Competitively binds to MC1 receptors on the surface of melanocytes, blocking the release of melanocyte-stimulating hormone at the source.
Decapeptide-4: Strengthens the attachment at the Dermal-Epidermal Junction (DEJ), enhancing the mechanical firmness of the skin.

The peptide system forms a collaborative signal relay within the dermis. While one peptide chain is responsible for turning on the synthesis switch, another is responsible for transporting necessary trace elements like copper and magnesium to ensure sufficient raw materials for enzymatic reactions.

Acetyl Hexapeptide-8 assumes a biochemical logic similar to botulinum toxin in the formula but works more gently. It interferes with the formation of the SNARE complex, reducing the release of the neurotransmitter acetylcholine. Through 28 days of continuous monitoring, skin roughness values around the eyes and forehead of testers decreased by about 20%, without affecting the natural movement of expression muscles. Subsequently, Copper Tripeptide-1 utilizes its high affinity to capture Cu2+ in tissue fluid. Copper ions are essential cofactors for synthesizing elastin. Under the action of GHK-Cu, the synthesis rate of elastin in the dermis is about 33% higher than the control group. This increase in protein density manifests as a shortening of skin rebound speed; suction pressure tests show that tissue recovery time is accelerated by an average of 0.5 seconds. Targeting environmental damage, Nonapeptide-1 exhibits specific melanin inhibition capabilities. It antagonizes α-MSH (melanocyte-stimulating hormone), keeping tyrosinase in a standby state rather than being activated. In environments with a UV intensity of level 3, skin areas pre-treated with Nonapeptide-1 show a melanin deposition index about 15% lower than untreated areas, effectively preventing Post-Inflammatory Hyperpigmentation (PIH).

Molecular weight distribution: Over 90% of peptide chains are smaller than 500 Da, ensuring high permeability.
Collagen increase rate: Under comprehensive action, Type I collagen production increased by 117%.
Cell migration rate: Speed of fibroblasts migrating to damaged areas increased by 14%.
Half-life: Optimized through amino acid sequences, maintaining biological activity in subcutaneous tissue for 48-72 hours.
Osmotic pressure range: Solution osmotic pressure is maintained at 280-320 mOsm/L, ensuring red blood cells do not shrink.

Decapeptide-4 primarily acts on the boundary between the basal layer and the dermis, stimulating the production of Laminin. Laminin acts like glue, firmly anchoring the epidermis to the dermis. As the concentration of this protein increases, the sagging sensation on the skin surface is physically relieved. Ultrasound scans show that the tightness of the DEJ layer exhibits a clear visual boundary line after three treatments. This peptide complex achieves biochemical balance within the 5ml volume of Curenex. Because the pH is precisely adjusted to around 7.2, the charge state of peptide molecules remains stable, avoiding mutual clustering or precipitation. The biological stability of the peptide chains is protected through level freeze-drying or sterile vacuum packaging. After entering the skin, these amino acid fragments are eventually decomposed into natural amino acids by tissue proteases and participate in normal human circulation. This residue-free metabolic path ensures long-term clinical safety, with a positive allergy test rate of less than 0.001%.

Clinical tracking data shows that on the 7th day after receiving peptide matrix treatment, Transepidermal Water Loss (TEWL) values on the skin surface decreased by 10%.

In a 6-month follow-up, the arrangement of dermal fibers changed from a messy parallel state to a tight cross-mesh structure. This structural reorganization allows the skin to exhibit 22% higher self-healing capacity and stronger optical transparency when facing external pressures like dryness and temperature changes. The combination of peptides and PDRN provides underlying support. PDRN is responsible for providing nucleotide raw materials for repair, while peptides issue specific construction instructions. This coordination of instructions and materials makes the tissue repair efficiency after a single introduction approximately 1.8 times higher than single-ingredient products.

Effect

Within 7-14 days after injection, 0.2% PDRN can increase the proliferation rate of fibroblasts by about 30%; non-cross-linked hyaluronic acid increases the water content of the stratum corneum by binding 1000 times its own weight in water. After 3 standard treatments (every 14 days), the skin melanin index usually decreases by 15%-20%, and the 15 peptides work synergistically to shallow facial expression lines.

Skin Tone and Pigment Metabolism

Curenex contains a 0.3% concentration of reduced Glutathione with a molecular weight of 307.3 g/mol, which easily penetrates the basal layer of the epidermis. After entering dermal tissue, the thiol group (-SH) of Glutathione actively attaches to dopaquinone, blocking the melanin synthesis path. The activity of free tyrosinase will decrease by 35%-40% within 48 hours, slowing melanin synthesis. The synthesis ratio of eumelanin (dark brown) decreases, while pheomelanin (light red or yellowish) increases. Using a professional facial skin imaging system (such as VISIA 7th Gen) in UV spot mode, it was observed that the area of deep pigment spots shrunk by 1.2 square millimeters within 14 days. Clinical observations by North American dermatologists on Fitzpatrick skin types III and IV subjects recorded specific pigment metabolism performance:

VISIA UV spot absolute score improved by an average of 18 points
Chloasma boundaries in the cheekbone area faded by 1.5 color grades
The diameter of superficial sunspots shrunk by 0.4 mm within 28 days
Free melanin particle density in the basal layer of the epidermis decreased by 22%

In addition to suppressing pigment generation, 0.2% PDRN participates in the exfoliation process of aging keratinocytes containing melanin. PDRN stimulates fibroblasts to secrete basic Fibroblast Growth Factor (bFGF), shortening the epidermal cell metabolism cycle from an average of 28 days to 21 to 24 days. When hyaluronic acid increases stratum corneum water content to over 20%, the refractive index of light on the skin surface changes. Well-hydrated keratinocytes align more flatly, allowing light to penetrate deep above the dermis and reflect out. Under natural light, the dark shadows caused by uneven pigment disappear, and the center area of the cheeks presents a Pantone 11-0602 TPX (very light translucent white) glow. Stabilizing pigment metabolism requires considering the external UV dose. Under the premise of daily SPF50+ broad-spectrum sunscreen application, the injection course has quantifiable retention periods for skin tone improvement:

The peak melatonin reduction period after a single injection lasts 10-14 days
Skin brightening effects after three consecutive treatments can last 3 to 4 months
Immediate Pigment Darkening (IPD) caused by UVA clears 30% faster
The antioxidant capacity index in serum peaks 48 hours after injection

Regarding Post-Inflammatory Hyperpigmentation (PIH), especially dark red or blackish-brown acne marks, the peptide components intervene in the repair of vascular dilation and pigment deposition in the late stages of inflammation. Oligopeptide-1 and the peptide complex cut off the pathway for inflammatory cells to release arachidonic acid, reducing local capillary dilation caused by histamine. The congestion period of new red acne marks is shortened from 15 days to 7 days, and the probability of turning into brown old marks is reduced by 45%. When dealing with stubborn chloasma, Western medical institutions precisely control the injection depth between 1.0 mm to 1.2 mm. This depth is at the junction of the basal layer of the epidermis and the papillary layer of the dermis, the area with the highest concentration of melanocytes. Using 32G or 34G ultra-fine for superficial dermis micro-droplet injection, the volume per injection point is controlled at 0.02 ml, with a drug diffusion radius of 3 mm. Micro-trauma caused by sticks triggers extremely mild acute inflammation, causing macrophages to gather around the wound to swallow metabolic waste and free melanin particles. Within 12 hours after injection, local erythema at the sites gradually fades, and macrophages transfer the swallowed pigment particles to the lymphatic system for discharge. Continuous observation for 3 months showed that in areas prone to pigment accumulation, such as the jawline and perioral area, the Evenness Index improved by 27%. Measuring light reflectance on the skin surface with a spectrophotometer yielded more precise pigment change parameters:

L* value (representing lightness) increased by an average of 2.3 units
a* value (representing redness) returned to baseline levels by the third day post-op
b* value (representing yellowness/blueness) decreased by 1.8 units, reducing sallowness
Overall Individual Typology Angle (ITA°) shifted toward a lighter skin tone range

Tissue Repair & Thickening

0.2% concentration PDRN with molecular weights between 50 to 1500 kDa can accurately bind to adenosine A2A receptors on the surface of fibroblasts. Within 48 hours after injection, the proliferation speed of fibroblasts increases by 30%, with large numbers gathering in the damaged dermal area. Synthesis of Collagen Type I and Type III begins to climb, providing substantive raw material supplementation for dermal tissue. The ratio of Type III collagen (often called baby collagen) secreted by fibroblasts changes, optimizing the ratio with Type I collagen from 1:4 to 1:3. Within a 21-day metabolic cycle, the density of the Extracellular Matrix (ECM) mesh structure increases. North American dermatology clinics used 20 MHz high-frequency ultrasound to measure the cheeks of subjects, obtaining quantitative data on dermal thickness. After completing two treatments spaced 14 days apart, dermal thickness in the cheekbone area increased by an average of 0.15 mm. Ultrasound imagery shows that the high-echogenic band representing collagen density widened significantly, and hollow-like dark areas within the tissue decreased by 22%. PDRN stimulates local tissue, upregulating the expression of Vascular Endothelial Growth Factor (VEGF) by 25%. Capillary branches in the papillary dermis begin to increase, with microcirculation blood flow speed increasing by an average of 12 mm/s, accelerating metabolic waste discharge from damaged tissues. 15 types of composite peptides target the Dermal-Epidermal Junction (DEJ), promoting an 18% increase in Laminin-5 synthesis. The wavy anchoring structure between the epidermis and dermis becomes deeper and tighter, effectively preventing the epidermis from micro-tearing after physical friction.

Measurement Period	TEWL Rate	Tissue Echogenicity	5% Lactic Acid Sting Tolerance
Before Injection	18.5 g/m²h	45 pixel units	1 min 30 sec
Day 14	14.2 g/m²h	58 pixel units	3 min 45 sec
Day 28	11.0 g/m²h	67 pixel units	5 min 20 sec

A manifestation of physical barrier thickening is the decrease in Transepidermal Water Loss (TEWL), with values dropping from 18.5 g/m²h to 11.0 g/m²h within 28 days. The skin’s tolerance threshold for external chemical stimuli is greatly improved, with the frequency of stinging and redness from acid-based skincare products reduced by 60%. Non-cross-linked hyaluronic acid molecules absorb and lock in water 1000 times their volume in tissue gaps. This physical hydration causes the volume of the dermal matrix to expand by 10%-15%, pushing up the sunken stratum corneum. Fine dry lines are smoothed within 72 hours post-injection, and the skin surface presents a plump, firm feel. Matrix Metalloproteinases (MMPs) are enzymes that destroy collagen, usually triggered by UV radiation. The peptide complex in the formula interferes with the secretion pathway of MMP-1, lowering its concentration in the skin by 40%. Already formed collagen fibers are protected from degradation, allowing the tissue-thickening effect to last for 3 to 6 months.

Keratinocyte renewal cycle stabilizes at 28 days, with old keratinocyte exfoliation rate increasing by 15%.
Bridge repair rate at deep dermal fiber breaks reaches 85% by Day 21.
Subcutaneous inflammatory messenger protein TNF-α concentration decreased by 30%, fading chronic redness.

In combination treatments with 1550nm non-ablative fractional laser, Curenex significantly shortens the healing time of thermal damage. Around the Microthermal Zones (MTZ) created by the laser, macrophage phagocytosis efficiency is improved. The shedding time of visible grid-like micro-scabs is shortened from an average of 7 days to 4 days, and the post-operative erythema period is reduced by 48 hours. European dermatologists recorded mechanical testing data for tissue strength in subjects with Fitzpatrick skin types I to III. A Cutometer was used to apply a continuous negative pressure of 450 mbar on the jawline area to test the dermis’s resistance to deformation. After three treatments, skin deformation parameters decreased by 12%, and elasticity recovery parameters rose by 15%. Operators usually choose 32G or 34G 4mm ultra-fine short to accurately deliver repair ingredients to target layers. Inserting at a 30-degree angle into the superficial dermis, the drug delivery per injection point is strictly controlled between 0.01 ml to 0.02 ml. The distance between adjacent injection points is 1 cm, ensuring that the drug diffusion surface can uniformly cover the entire damaged facial area.

Fine Lines and Skin Elasticity

The 15 types of composite peptides in Curenex have extremely small molecular weights, usually between 500 to 2000 Daltons. Within 24 hours of entering the dermis, peptide molecules penetrate fibroblast membranes and bind with internal receptors. 70% of the substance in the dermal mesh structure is collagen; peptides prompt fibroblasts to increase Type I collagen secretion by 25%. Acetyl Hexapeptide-8 blocks the pathway of nerve endings releasing acetylcholine (ACh), weakening the micro-contraction force of superficial facial muscles. Crow’s feet 1.5 cm outside the eye corner are reduced by an average of 0.8 mm in depth under dynamic pressure. Physical tension in the epidermis is released, and the conversion time from dynamic to static wrinkles is extended by about 6 months. Western anti-aging research centers used a Cutometer MPA 580 probe to suck the cheek skin of subjects 20 times under 400 mbar negative pressure. After 3 months of consecutive monthly targeted injections, multi-dimensional mechanical parameter changes were obtained:

R0 (Skin Distensibility) decreased by 14.5%, showing the tissue became firmer.
R2 (Overall Elasticity) increased by 18.2%, with faster rebound speed.
R5 (Net Elasticity) increased by 0.12, with reduced tissue fatigue.
R7 (Biological Elasticity) improved by 16%, enhancing collagen mesh support.

The volume of horizontal wrinkles in the forehead area showed a significant reduction under a 3D skin imaging system (PRIMOS). 0.2% PDRN coordinates with peptides to provide structural filling for collapsed subcutaneous tissue, reducing the static forehead wrinkle volume by 1.4 cubic millimeters. The fat pad above the nasolabial fold, pulled by the tightening collagen fiber network, showed a 1.2 mm reduction in drooping displacement. Non-cross-linked hyaluronic acid absorbs 1000 times its volume in water around pore walls, pressing inward on pore channels. Data from VISIA skin analysis confirms that the number of dilated pores with a diameter greater than 0.3 mm on the center of the cheeks decreased by 21%. The cross-linking reaction between water and collagen within the Extracellular Matrix (ECM) becomes active, with Glycosaminoglycan (GAGs) concentrations rising by 30%. Pressing with a finger on the tissue below the cheekbone, the time to recover to flatness shortened from 2.5 seconds to 1.8 seconds. PDRN uses deoxyribonucleotide chains to provide DNA repair raw materials for aging fibroblasts. The telomere shortening speed of fibroblasts in the aging phase slows down, and the active secretion period is extended by 20%. Newly generated elastin molecules cross-link to form a mesh structure, reducing the skin’s sagging angle in the jawline area by 4 degrees. For middle-aged subjects with Fitzpatrick skin types II to IV, researchers tracked morphological changes in fine lines around the eyes and mouth. By Day 28 after a full course (3 sessions, every 14 days), instruments read the following values:

Fine lines 2 cm below the eyes shortened by an average of 2.4 mm.
Surface roughness (Ra value) of perioral radial wrinkles decreased by 15%.
Skin texture anisotropy index decreased, with more uniform texture direction.
Volume of epidermal micro-ridges increased by 8%, showing plumpness.

Lysyl Oxidase (LOX) activity increases under peptide stimulation, prompting procollagen molecules to cross-link into tough, mature collagen fibers. The ability of the dermis to resist mechanical tearing improves, and fine epidermal folds are pushed flat by the expanding underlying tissue. Dermal thickness increased by an average of 0.18 mm after measurement with high-frequency ultrasound. To maximize the elasticity-lifting effect, operators use 4mm 32G sharp for deep dermis injection at facial ligament anchor points. The injection dose around the zygomatic and mandibular ligaments is increased to 0.05 ml per point, with the medicine forming a 4mm diameter micro-reservoir in the tissue. Mild acute inflammation prompts macrophages to release Platelet-Derived Growth Factor (PDGF), recruiting more fibroblasts to migrate to the puncture points. 72 hours post-injection, local Elastin mRNA expression is upregulated 2.5 times. The facial contour visually presents an upward lifting sensation, and jawline definition improved by 11%. High concentrations of active ingredients establish a continuous-release nutrient pool in the dermis, keeping collagen synthesis active for several months. To counter the continuous collagen loss brought by gravity and natural aging, Western dermatology clinics usually recommend following a specific maintenance schedule:

After the initial 3 treatments, tissue elasticity reaches its peak data value.
From the 3rd month, the Type I collagen production rate returns to 110% of baseline.
A 2 ml full-face top-up is recommended every 4 to 6 months.
Maintenance injections can slow the rate of elasticity loss by 40%.

In a 12-month long-term follow-up, subjects who followed the maintenance injection plan still maintained an 18% improvement in overall facial fine line depth compared to before injection.

Usage

The standard single dose for Curenex is 5ml (one ). In dermatology clinics, operators usually use 32G ultra-fine for dermal injection (1.2mm-1.5mm depth) or work with microneedling (MTS) devices with lengths of 0.25mm-1.0mm. A complete course is 3 to 5 sessions, with an interval of 10 to 14 days between two adjacent sessions. Transdermal absorption rates of PDRN and Glutathione peak within 48 hours after introduction. After completing 3 sessions, facial stratum corneum water content typically increases by 15%-20%. A 5ml introduction is recommended every 60 days for maintenance.

Different Introduction Methods

In dermatology clinics in Los Angeles or Seoul, practitioners often use 1cc Luer-lock with 32G x 4mm ultra-fine to administer 5ml of Curenex. The bevel faces up, inserted into the epidermis at a 30 to 45-degree angle, with the depth strictly controlled between 1.2mm to 1.5mm, targeting the papillary dermis. Each push delivers 0.02ml to 0.05ml of solution, forming a small wheal approximately 3mm in diameter on the skin surface. A full 5ml solution is distributed into 100 to 120 dense injection points across the face. The physical distance between points is kept at 1.0 cm to 1.5 cm, and PDRN uniformly diffuses to surrounding 5mm tissue within 48 hours. For thinner skin areas, doctors adjust the pressure and angle of delivery. Dermal thickness around the eyes is only 0.5mm, so operators insert the at 0.5mm or even shallower. The forehead has less than 2mm of subcutaneous fat, so the injection angle is lowered from 45 degrees to a 15-degree flat thrust. Standard consumable and parameter specs for manual single-operation include:

5% Lidocaine compound anesthetic cream, applied full-face for 30 minutes.
2% Chlorhexidine alcohol solution for 2 full-face physical wipes for disinfection.
32G half-inch (13mm) long for extracting liquid from the glass ampoule.
The 0.02ml liquid in the wheal takes 24 to 48 hours to subside.

Using a 9-water-light, such as the V2 common in North American clinics, can improve the delivery efficiency of the 5ml solution. The device is equipped with 31G or 32G 9-array blocks. The vacuum suction probe lifts the skin by 2mm to 3mm, and then 9 simultaneously puncture to the preset 1.0mm depth. The vacuum pump inside the equipment generates 200mBar to 500mBar negative pressure, controlling the drug leakage rate to below 5%. The operator sets the single output per on the screen to 0.01ml to 0.025ml. One 5ml will complete 150 matrix shots within 10 minutes, creating 1350 micro-pores. The negative pressure release delay is set to 0.5 seconds to ensure liquid filling at the 1.0mm depth before withdrawal. For cheek areas with large pores, the negative pressure level is set higher to 4; for forehead areas with thin tissue, it is lowered to 2, with the injection depth adjusted to 0.8mm. Electric microneedling (MTS) devices combined with Curenex are more common in European beauty salons. The operator holds a microneedling pen with a 12-or 36-disposable chip, moving across the face in a vertical stamping or circular sliding motion. The motor speed is constant between 5000 RPM to 7000 RPM. The device creates over 300 micro-physical channels per square centimeter per second. The operator uses a sterile dropper to apply 0.5ml of solution on one side of the cheek; the microneedling pen sweeps over the area within 3 seconds, and the liquid penetrates along the 0.02mm diameter mechanical channels due to gravity and capillary action. MTS device depth changes with facial anatomy. The operator rotates the pen body dial while moving the device. The operating depth for cheeks and jawline is set to 1.0mm to 1.5mm; forehead and nose bridge are lowered to 0.5mm; around the orbits, a very shallow depth of only 0.25mm is used. Parameter specs for 5ml solution microneedling in Western beauty salons:

Cross-circular motion on cheek areas, with overlapping coverage reaching 50%.
Full face divided into 6 zones, with 0.8ml solution evenly allocated to each zone.
The remaining 0.2ml is used for secondary application and pressing on chin pigment areas.
Point-like bleeding of 0.1mm diameter during the procedure is a normal endpoint reaction.
After the procedure, use 4°C saline gauze for a 15-minute cold compress.

Derma Rollers are often used by North American users for home-based delivery. The roller cylinder surface is embedded with 192 to 540 medical-grade stainless steel microneedles. Home-use length specs do not exceed 0.5mm, only penetrating the stratum corneum to reach the 0.1mm thick epidermal basal layer. Before operation, the user soaks the roller in 75% isopropyl alcohol solution for 20 minutes. The face is divided into four quadrants: left cheek, right cheek, forehead, and chin. Apply 1.0ml of solution to a single quadrant first, and the roller moves 4 to 5 times in horizontal, vertical, and two diagonal paths. A 192-roller can produce about 2000 puncture holes in a single area roll. Downward pressure applied by the user is controlled between 150 to 200 grams, stopping once the skin surface shows a slight, uniform pink color. A 5ml glass ampoule must be completely used within 1 hour after opening at room temperature. Micro-injuries caused by different devices (0.1mm to 1.5mm) can activate macrophages. The 0.2% PDRN concentration within the 5ml liquid diffuses in the dermis at a 1.0mm depth, with over 60 times more contact surface area with dermal collagen fibers compared to manual topical application. The dermal injection method shows a 20% value increase on water testing meters after 28 days. The 0.25mm depth microneedling introduction shows a 12% value decrease on melanin index meters. Los Angeles clinics often provide combined protocols. A nurse uses a 32G to inject 3ml of solution at a 1.2mm depth into both cheeks. The remaining 2ml of solution is introduced into the forehead, nose, and chin via a 0.5mm spec 36-microneedling pen, taking a total of 15 minutes to distribute the 5ml liquid.

Standard Course Timing

Dermatologists in Gangnam, Seoul, usually set a course of 5 sessions of single 5ml as a complete basic cycle. The first introduction on Day 1 mainly establishes dermal hydration channels, with non-cross-linked hyaluronic acid starting to bind surrounding water molecules within 24 hours of entering the 1.2mm depth. 72 hours post-procedure, the user’s cheek stratum corneum water meter (Corneometer) reading usually jumps from a baseline of 35 to 52. Transepidermal Water Loss (TEWL) briefly rises by 10% in the 48 hours after the first skin break, then returns to normal by the 5th day. The 1000 kDa molecular weight hyaluronic acid in the tissue degrades by about 40% by Day 14. At this time, the clinic schedules the 2nd 5ml solution introduction, with the injection depth remaining unchanged at 1.5mm. The second introduction relies on the 0.2% PDRN concentration binding with fibroblast surface receptors in the papillary dermis. In vitro cell culture data indicates that 72 hours after PDRN contacts human fibroblasts, intracellular ATP synthesis increases by 15%. New blood vessels appear in the operation area by Day 21, with blood oxygen saturation increasing by 3%. Entering Day 28, the user receives the 3rd 5ml solution introduction. The 15 types of peptides accumulated in the dermis begin to show tissue remodeling data. The VISIA skin detection system at this time point usually shows that the number of fine lines with a depth of 0.05mm in the forehead area has decreased by 12 lines.

Time Point	Total Dose	Stratum Corneum Water Content	TEWL	VISIA Spot Score	Collagen Ultrasound Echogenic Area
Day 0	0 ml	35.2 AU	15.4 g/m²/h	412.5	45.2%
Day 14	10 ml	48.6 AU	14.8 g/m²/h	405.2	46.8%
Day 28	15 ml	53.4 AU	12.1 g/m²/h	382.1	51.5%
Day 42	20 ml	58.1 AU	10.5 g/m²/h	350.8	58.3%

Day 28 to Day 42 is the peak period for Glutathione in the solution to exert its antioxidant effects. The ingredient blocks the tyrosinase synthesis pathway in melanocytes, causing free radical concentrations in cheek tissue to decrease by 22%. In the 4th 5ml introduction on Day 42, nurses in Manhattan, New York, usually increase the push dose per point of the 32G from 0.02ml to 0.03ml. Locally accumulated active ingredients create quantifiable physical changes in different facial anatomical zones:

Skin thickness 1.5 cm below the orbit increased from 0.61mm to 0.65mm.
Skin elasticity meter measurements in the jawline area improved by 8.5%.
The number of dilated pores larger than 0.1mm on the sides of the nose decreased by about 18.
Bilateral cheek Erythema Index decreased by 14 units under a spectrophotometer.

The 5th introduction on Day 56 marks the end of the basic cycle. At this time, high-frequency skin ultrasound (20 MHz) detects a significant thickening of the echogenic band in the reticular dermis. Type I collagen fibers stimulated by PDRN reached a 58.3% high-echogenic area ratio, with tissue density increasing by 13.1% compared to Day 1. After completing the total delivery of 25ml solution, facial tissue enters a stable metabolic period lasting 60 days. The half-life of large molecular proteins in the solution within the dermis is approximately 45 to 50 days. Around Day 116, the degradation rate of hyaluronic acid reaches 85%, and the collagen proliferation rate returns to baseline. To keep VISIA test data from reversing by more than 10%, doctors schedule the 1st single 5ml maintenance session on Day 116. The injection depth for maintenance is uniformly adjusted to 0.8mm at the lower edge of the epidermal basal layer. The single-point push dose is rolled back to 0.015ml/point, creating only 300 wheals to replenish water loss in the local extracellular matrix. Thereafter, every 8 weeks (about 56 to 60 days), the patient needs to repeat one maintenance introduction of a single at a 0.8mm depth. If the interval exceeds 120 days, the free radical clearance rate of antioxidant components in the 5ml solution will drop below 5%. By then, the microcirculation channels in the tissue will close, and the patient will need to restart the basic intensive course of 5 sessions at 14-day intervals.

Facial Dosage Distribution

The average facial surface area of an adult female is between 400 to 600 square centimeters; the total 5ml volume must be strictly divided according to anatomical thickness. The bilateral cheek areas occupy the largest surface area, with 2.5ml of solution allocated. Dermal thickness in this area measures 1.5mm to 2.0mm, and its reticular layer contains dense collagen fiber networks that can accommodate a larger volume of liquid without causing subcutaneous nodules.

Left Cheek: 1.25ml solution allocated, using a 32G to create 40 to 45 wheals.
Right Cheek: 1.25ml solution allocated, wheal physical distance kept at 1.0 cm in an equilateral triangle array.
Injection Depth: Strictly controlled at 1.2mm, perpendicular to the papillary dermis.
Single Point Discharge: 0.03ml liquid pushed, forming a 3mm diameter micro-bump above the epidermis.

The operation shifts upward to the forehead area, which consumes 1.0ml of liquid. Subcutaneous fat in the forehead is extremely thin, with the total thickness of dermis and epidermis dropping to 0.8mm to 1.2mm. To prevent liquid from accumulating and migrating above the periosteum, the nurse lowers the 32G ‘s insertion angle from 45 degrees to 15 degrees. The 1.0ml solution is divided into 50 extremely tiny injection points, with the operator’s index finger push pressure reduced by 30%.

Central Forehead: 0.6ml consumed, distributed horizontally across 30 equidistant points.
Glabellar Area: 0.2ml consumed, injection depth restricted to a very shallow 0.5mm.
Bilateral Temples: 0.1ml allocated each, avoiding superficial temporal artery branches.
Metabolic Time: Due to lower microvascular density, wheals take 36 to 48 hours to subside.

The periorbital area is strictly limited to a 0.5ml quota. Skin under the eyes is the thinnest structure on the human face, with a total thickness of only 0.4mm to 0.6mm measured by calipers. Excessive liquid injection can block periorbital lymphatic drainage and cause edema for up to 72 hours. The 0.5ml solution is split in half, with only 0.25ml allocated to each infraorbital area. The only enters 0.25mm into the basal layer, with each point emitting a 0.01ml micro-droplet, and point spacing reduced to 0.5 cm. The remaining 1.0ml of solution is targeted for the chin and perioral network. The perioral area epidermis undergoes tens of thousands of mechanical pulls from 43 facial expression muscles daily, with local hyaluronic acid metabolism 15% higher than in the cheeks. The chin area receives 0.6ml injection, with the tip entering at a 1.0mm depth to improve tissue laxity. The nasolabial folds and upper lip area share the final 0.4ml, with the drug precisely delivered to the 1.5mm deep dermal-epidermal junction.

Mentalis muscle area: 0.6ml consumed, divided into 20 points of 0.03ml each.
Perioral orbicularis oris periphery: 0.2ml consumed, using a 0.5mm superficial stamp injection.
Nasolabial fold depression: 0.2ml consumed, at a 30-degree angle to the skin, tilted into 1.2mm.
Consumable replacement: After completing 100 punctures, a brand new 34G must be swapped to maintain sharpness.

During the 20-minute liquid transfer and push process, the mechanical dead space of the hub will cause a physical loss of approximately 0.1ml. Nurses in some North American clinics will use 29G drawing with 0.5cc insulin zero-dead-space to reduce the hub residue rate by 2%. When the 5ml liquid is completely distributed among the 4 facial anatomical zones, free 0.2% PDRN molecules begin to diffuse in the 22°C subcutaneous environment. 150 isolated wheals across the face will perform a 0.5 cm radial penetration in 24 hours, eventually merging into a uniform 1.0mm thick hydration layer. If the clinic adopts a 36-electric microneedling pen, the spatial distribution logic of the 5ml liquid will physically transform. Because the liquid is exposed to air, the natural evaporation rate within 3 minutes at 22°C room temperature reaches 15%. The microneedling operator will apply 1.5ml solution on the left cheek and another 1.5ml on the right cheek. The device motor moves over the skin at 6000 RPM, creating over 500,000 mechanical micro-channels at depths of 0.5mm to 1.0mm within 10 minutes. The remaining 2.0ml is added in portions during the forehead and chin operation. `html Curenex is a Korean complex skin booster that integrates repair and brightening. Its core ingredients include PDRN (Salmon DNA), 15 types of peptides, Glutathione, and Hyaluronic Acid. In clinical use, it is recommended to be administered by a professional physician through mesotherapy. A standard course usually consists of 3-5 sessions, with an interval of 2-3 weeks between each session.